Scientific Advisory Board, Institute for Cancer Research
The Institute for Cancer Research has from Jan 2021 renewed and rotated its Scientific Advisory Board that provide regular reviews of scientific output, quality and performance and gives advice on research strategy. The SAB consist of six highly distinguished scientists that represent a variety of different scientific backgrounds in basic, translational and clinical cancer research. Collectively, they have a great set of complementary competencies and a long track record of scientific and strategic leadership experience. They are thus very well equipped for evaluating the scientific activity at the institute.
|Professor Carl-Henrik Heldin, Department of Medical Biochemistry and Microbiology, Uppsala University, SAB Chair
|Professor Carl Figdor, Head, Dept of Tumor Immunology, Institute for Molecular Life Sciences, Radboud UMC, The Netherlands
|Professor Margaret C. Frame, FRSE, FmedSci, OBE, Professor of Cancer Research and Director, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
|Professor Ruth Palmer, Institute of Biomedicine, University of Gothenburg
|Professor Karen-Lise Garm Spindler, Department of Experimental Clinical Oncology, University of Aarhus; Consultant Oncologist, Aarhus University Hospital
|Professor Giulio Superti-Furga, Scientific Director, Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, and Professor for Medical Systems Biology, Center for Physiology and Pharmacology Medical University of Vienna
Web-page and Biography: https://cemm.at/research/groups/giulio-superti-furga-group/
Read about the ICR SAB meeting in January 2021 here.